FDA gets to grips with pharmacogenomics:
This article was originally published in Clinica
Executive Summary
The US FDA wants to meet with officials from industry to learn about the demands involved in developing pharmacogenomic products. The agency will use the comments to help shape an upcoming guidance document on the topic. The day-long meeting at the Marriott Crystal Gateway Hotel in Arlington County, Virginia, will take place on July 29 from 8 am. Register by July 26, and submit comments by August 30. For more information, contact the meeting's co-sponsor, the Drug Information Association at email: [email protected]
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.